Free US stock valuation models and price target projections from professional analysts covering Wall Street expectations. We help you understand fair value estimates and potential upside or downside scenarios for any stock.
This analysis covers Bristol Myers Squibb’s (BMY) Q1 2026 financial results, which posted modest year-over-year (YoY) growth that outperformed consensus estimates, alongside the firm’s disclosed late-stage pipeline catalysts aimed at mitigating upcoming patent expiries for its top-selling drug Eliqu
Bristol Myers Squibb (BMY) - Mixed Q1 Earnings Beat Supported By High-Impact Late-Stage Pipeline Catalysts - Acceleration Picks
BMY - Stock Analysis
3048 Comments
1160 Likes
1
Tralynn
Daily Reader
2 hours ago
Seriously, that was next-level thinking.
👍 287
Reply
2
Manerva
Community Member
5 hours ago
I don’t know what this is but it matters.
👍 145
Reply
3
Jolly
Elite Member
1 day ago
This feels like a hidden level.
👍 284
Reply
4
Natlie
Elite Member
1 day ago
Such flair and originality.
👍 206
Reply
5
Aprilia
Active Reader
2 days ago
I wish I didn’t rush into things.
👍 281
Reply
© 2026 Market Analysis. All data is for informational purposes only.